Fluzoparib with apatinib vs chemo for advanced breast cancer
Treatments studied
Part of Cancer clinical trials.
This trial tests a combination of two oral targeted drugs (fluzoparib and apatinib) against standard chemotherapy for women with advanced, HRD-positive, HER2-negative breast cancer. It may be an option if you have already received some treatments but not too many.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a woman between 18 and 70 years old with breast cancer that has spread to other parts of the body.
- Your cancer is HER2-negative (a type of breast cancer) and has a positive HRD test (meaning your tumor has trouble repairing DNA).
- You have already received endocrine therapy (hormone treatment) if your cancer is hormone receptor positive.
- You have had no more than two types of chemotherapy for your advanced cancer, and your last treatment helped your cancer shrink or stay stable for at least 6 months.
- You are in reasonably good health otherwise, with normal blood counts, liver and kidney function, and no serious heart problems.
- You are not pregnant and agree to use effective birth control during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a combination of two targeted therapies, fluzoparib (a PARP inhibitor) and apatinib (a blood vessel blocker), as maintenance treatment after initial chemotherapy for advanced ovarian cancer. The goal is to see if this combination helps keep the cancer from coming back longer than usual.
This study tests whether adding the drug apatinib mesylate to your doctor's chosen treatment can help slow or shrink advanced breast cancer. It's for people whose cancer has continued to grow despite prior hormonal therapy and CDK4/6 inhibitor treatment.
This trial tests two oral medications (fluzoparib and apatinib) taken daily as maintenance therapy after your ovarian cancer has responded to chemotherapy. The goal is to keep the cancer from returning for as long as possible.
This trial tests a combination of two oral drugs—fuzuloparib (a PARP inhibitor) and apatinib (which blocks blood vessel growth to tumors)—given before surgery for advanced ovarian cancer that cannot be removed right away. It is for people whose tumors have a specific genetic marker (HRD positive) and who have not had prior cancer treatment.
This trial tests a combination of two oral medications (fluzopril and apatinib) as maintenance therapy after chemotherapy, for patients with platinum-resistant ovarian cancer. The goal is to see if this combo helps keep the cancer from growing longer than usual.
This study tests a combination of an immunotherapy drug (adebrelimab) and a PARP inhibitor (fluzoparib) for people with HR-positive, HER2-negative breast cancer that has spread. It may help if your tumor has a specific genetic feature called HRD-positive.
Hear when a new Fludzoparib" and Anti-angiogenic trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.